Takara Bio aims to resolve ESG issues while creating social value through business activities
Guided by our corporate philosophy of “contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy,” and from the perspective of increasing our medium- to long-term corporate value, Takara Bio Group is working to solve various social challenges concerning sustainability, in the area of wellness as well as other areas, through our business activities. We aim to strike a balance between becoming a sustainable company and achieving sustained growth of Takara Bio Group. As part of this effort, we identified materialities (important issues) and are collaborating with stakeholders and partnering with Takara Holdings Group to carry out sustainability management to help solve social issues.
Identification of materialities
We identified eight materialities that are most relevant to the Group’s business, with additional consideration to stakeholder expectations, that we will look to as we carry out our sustainability activities. As we tackle social issues with our central focus on these eight materialities, we aim to strike a balance between becoming a sustainable company and achieving sustained growth of Takara Bio Group.
System for implementation
The Group established a Takara Bio Group Sustainability Promotion Committee chaired by the President of Takara Bio to implement sustainability activities, and is carrying out initiatives related to each materiality.
We consider the preservation of the global environment and the harmonious conduct of our business activities to be an important topic in the way we manage the company, and to that end we strive to observe the applicable environmental laws, ordinances, and regulations as we proactively take part in natural conservation activities and work to conserve resources and energy. We are working to reduce the environmental burden generated by all of our processes, ranging from R&D and the procurement of raw materials to production, distribution, sales, and consumption.
Takara Bio is making advancements in the development of gene therapies driven by our proprietary technologies, aimed at patients of rare diseases and serious diseases such as cancer for which treatment methods are yet insufficient. In addition, we make day-to-day efforts to contribute to society by providing researchers worldwide with the research reagents and kits that are essential to leading-edge life sciences research.
Takara Bio will pursue sustainable growth and enhancement of our corporate value in the medium- to long-term by fulfilling our social responsibility as a corporation, and by meeting the expectations of our various stakeholders, including our shareholders.